REGN5715 / Regeneron 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
REGN5715 / Regeneron
NCT06602739: A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy

Recruiting
3
50
Canada, US
REGN5713, Bremzalerbart, REGN5715, Atisnolerbart, Placebo
Regeneron Pharmaceuticals
Allergic Conjunctivitis
04/25
08/25
NCT05430919: Efficacy of the Anti-Bet v 1 Monoclonal Antibodies (Given Subcutaneously) to Reduce Allergic Rhinitis and Conjunctivitis Symptoms and Skin Test Reactivity Upon Exposure to Birch Allergen in Adult Participants

Completed
2
217
Canada
REGN5713, REGN5714, REGN5715, Placebo
Regeneron Pharmaceuticals
Allergic Rhinitis, Conjunctivitis
07/23
07/23

Download Options